Home › NDC Lookup › RxCUI directory › RxCUI 1037179

Dabigatran etexilate 75 MG Oral Capsule — RxCUI 1037179

RxNorm drug concept · Semantic clinical drug
RxCUI 1037179 Semantic clinical drug · SCD ● Current RxNorm concept 40 FDA products 63 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1037179
Official nameDabigatran etexilate 75 MG Oral Capsule
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asdabigatran etexilate 75 MG (as dabigatran etexilate mesylate 86.48 MG) Oral Capsule
FDA products mapped40
Package NDCs mapped63
Reported Medicaid activity (SDUD)36,481 prescriptions · 47 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Dabigatran Etexilate: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • It’s a blood thinner. It lowers stroke risk in non-valvular atrial fibrillation and treats or prevents blood clots in the legs and lungs. Some forms are approved for children with...
  • Swallow capsules whole, with or without food, as your prescriber directs. Don’t open, chew or break them. Don’t swap between forms on your own.
  • No. Stopping early raises your risk of clots and stroke. Talk to your doctor first so they can plan coverage if needed.
  • Stomach upset, indigestion, nausea and diarrhea are common, along with bleeding. Call us or your doctor about unusual or heavy bleeding.
📖 Read our full Dabigatran Etexilate guide →

🕸️ Concept Web — How Dabigatran etexilate 75 MG Oral Capsule Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Dabigatran etexilate 75 MG Oral Capsule RxCUI 1037179

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Dabigatran etexilate 1037042
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Pradaxa 1037046
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Dabigatran etexilate Oral Capsule 1037044
    • Dabigatran etexilate Oral Product 1156646
    • Dabigatran etexilate Pill 1156647
    • Dabigatran etexilate Oral Capsule [Pradaxa] 1037048
    • Pradaxa Oral Product 1184616
    • Pradaxa Pill 1184617
    • Oral Capsule 316965
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Dabigatran etexilate 75 MG SCDC · 1037178
  • Dabigatran etexilate Oral Capsule SCDF · 1037044
  • Dabigatran etexilate Oral Product SCDG · 1156646
  • Dabigatran etexilate Pill SCDG · 1156647

Brand-Name Concepts

  • Dabigatran etexilate 75 MG Oral Capsule [Pradaxa] SBD · 1037181
  • Dabigatran etexilate 75 MG [Pradaxa] SBDC · 1037180
  • Dabigatran etexilate Oral Capsule [Pradaxa] SBDF · 1037048
  • Pradaxa Oral Product SBDG · 1184616
  • Pradaxa Pill SBDG · 1184617
  • Pradaxa BN · 1037046

📦 FDA Products & Package NDCs

40 products · 63 package NDCs
63 package NDCs map to RxCUI 1037179 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
62332-0636-60 60 CAPSULE in 1 BOTTLE (62332-636-60) Dabigatran Etexilate Alembic Pharmaceuticals Inc. 2024-06-14
67877-0474-60 60 CAPSULE, COATED PELLETS in 1 BOTTLE (67877-474-60) Dabigatran Etexilate Ascend Laboratories, LLC 2022-06-20
67877-0475-60 60 CAPSULE, COATED PELLETS in 1 BOTTLE (67877-475-60) Dabigatran Etexilate Ascend Laboratories, LLC 2022-06-20
67877-0624-31 10 BLISTER PACK in 1 CARTON (67877-624-31) / 6 CAPSULE, COA... Dabigatran Etexilate Ascend Laboratories, LLC 2025-09-12
67877-0624-60 60 CAPSULE, COATED PELLETS in 1 BOTTLE (67877-624-60) Dabigatran Etexilate Ascend Laboratories, LLC 2025-09-12
72205-0202-34 6 BLISTER PACK in 1 CARTON (72205-202-34) / 10 CAPSULE in 1... DABIGATRAN Novadoz Pharmaceuticals LLC 2024-10-01
72205-0202-60 60 CAPSULE in 1 BOTTLE (72205-202-60) DABIGATRAN Novadoz Pharmaceuticals LLC 2024-05-24
72205-0203-34 6 BLISTER PACK in 1 CARTON (72205-203-34) / 10 CAPSULE in 1... DABIGATRAN Novadoz Pharmaceuticals LLC 2024-10-01
72205-0203-60 60 CAPSULE in 1 BOTTLE (72205-203-60) DABIGATRAN Novadoz Pharmaceuticals LLC 2024-08-14
72205-0204-34 6 BLISTER PACK in 1 CARTON (72205-204-34) / 10 CAPSULE in 1... DABIGATRAN Novadoz Pharmaceuticals LLC 2024-10-01
72205-0204-60 60 CAPSULE in 1 BOTTLE (72205-204-60) DABIGATRAN Novadoz Pharmaceuticals LLC 2024-05-24
72865-0272-60 60 CAPSULE in 1 BOTTLE (72865-272-60) Dabigatran Etexilate XLCare Pharmaceuticals, Inc. 2023-08-01
72865-0273-60 60 CAPSULE in 1 BOTTLE (72865-273-60) Dabigatran Etexilate XLCare Pharmaceuticals, Inc. 2023-08-01
Observed labelers: Alembic Pharmaceuticals Inc. (7) · Alembic Pharmaceuticals Limited (7) · Aurobindo Pharma Limited (6) · Boehringer Ingelheim Pharmaceuticals Inc. (6) · Camber Pharmaceuticals, Inc. (6) · Novadoz Pharmaceuticals LLC (6) · +9 more — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.